A health economics researcher explains why purchase price is the smallest number in a clinical trial technology decision and what gets left off the budget.
- Research Design Mistakes Even Experienced Analysts Still Make
- The Infrastructure Behind Virtua Health's Push Toward 1.5 Million Studies A Year
- A Framework For Deploying AI In Clinical Trials Without The Hype
- Why Younger Clinical Researchers Are More Wary Of AI Than Their Elders
- Your EDC Query Count Is Trying To Tell You Something
- Inside The Rush To Accelerated Approval: A Consultant's View
- Why Virtua Health's AI Committee Gives IT The Review, Not The Vote
- Building Effective, Retrospective Decision-Grade Disease Registries
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
eConsent: The Missing Ingredient To More Engaging Clinical Trials
Electronic consent promotes better trial experiences, but many sites and sponsors are wary of giving up paper-based processes. Consider their reasons for caution and how teams can prepare for the switch.
-
Come To The Dark (Mode) Side
Many of the decisions made by a product team start as suggestions from a user community of clinical professionals. While planning the development of a recently launched CTMS, a focus group was led where clinical professionals weighed in on potential improvements for a new system.
-
Running Compliant Studies Without Enterprise EDC Overhead
Low-complexity medical device and IVD studies often fall between enterprise EDC systems and spreadsheets. This webinar shows how a compliant, audit-ready alternative works in practice.
-
Build Versus Buy: What's The Best Tech Tool For Study Activation?
In the case of study activation, there are several compelling reasons that buying an appropriate purpose-built system is a better choice than taking on the challenge of building a study activation tool.
-
Nevro Eliminates Majority Of Source Data Verification With ePRO And EDC
Read how a global medical device company was able to unlock new efficiencies by implementing data collection via electronic patient-reported outcome assessments.
-
Why "Good Enough" Data Is Good Enough For Agentic AI
Overcome 'data paralysis' and learn why you don’t need perfect data to start leveraging AI and its benefits, and why starting today is much better than waiting for 'perfect.'
-
Cytokine Release Syndrome Monitoring
Here we introduce an innovative risk-monitoring solution aimed at mitigating Cytokine Release Syndrome (CRS), a critical complication in immunotherapy that often leads to prolonged hospitalization.
-
Accelerated Approval As The New "Norm" In Gene Therapy For Rare Diseases
Gene therapy has revolutionized treatment prospects for rare genetic disorders by enabling corrective or replacement strategies at the molecular level.
-
eCOA In Oncology Trials: A Tool To Simplify
Accurate quality of life data is critical in oncology. eCOA unified with IRT streamlines trials, improves data collection, and enhances site user experiences across therapeutic areas.
-
Digital Measurement Of Nocturnal Scratch In Atopic Dermatitis
A major challenge in managing atopic dermatitis (AD) is the lack of objective tools to measure the impact of nocturnal scratching, but new digital measurement solutions could address this gap.
- The Hidden Costs Of Clinical Trial Technology Nobody Budgets For
- What South Africa's Trial Sites Teach Global Clinical Research
- Research Design Mistakes Even Experienced Analysts Still Make
- The Infrastructure Behind Virtua Health's Push Toward 1.5 Million Studies A Year
- A Framework For Deploying AI In Clinical Trials Without The Hype
RECENT NEWSLETTERS
- 10.22.26 -- AI, RWE, And IRT Are Exposing Trial Workforce Gaps
- 10.15.26 -- AI, Site Burden, And Vendor Risks Are Testing Trials
- 10.08.26 -- AI, RTSM, And Trial Systems Are Still Breaking Down
- 10.03.26 -- Best Of September: AI, Wearables, And Trial Workflow Gaps
- 10.01.26 -- AI, Data Integrity, And Wireless Gaps Are Reshaping Trials